The Federal Drug Administration is moving toward emergency approval of remdesivir for the treatment of COVID-19 following positive results in patients, according to National Institute of Allergy and Infectious Diseases director Dr.
Anthony Fauci and Gilead, the maker of remdesivir.A federal trial conducted by Gilead on 1,063 COVID-19 patients found that those receiving remdesivir recovered in 11 days on average, while those given a placebo took 15 days.